ABSTRACT
Background Racial and ethnic minority men who have sex with men (MSM) are disproportionately affected by HIV/AIDS in Los Angeles County (LAC), an important epicenter in the battle to end HIV.
Objective To examine tradeoffs between effectiveness and equality of PrEP allocation strategies among different racial and ethnic groups of MSM in LAC.
Design, Setting, and Population We developed a microsimulation model of HIV among MSM in LAC using county epidemic surveillance and survey data to capture demographic trends and subgroup-specific partnership patterns, disease progression, patterns of PrEP use, and patterns for viral suppression.
Intervention We simulated interventions where an additional 3000, 6000, or 9000 PrEP prescriptions are provided annually in addition to current levels, following different allocation scenarios to each racial/ethnic group (Black, Hispanic, or White).
Measurements We estimated cumulative infections averted and measures of equality, after 15 years (2021-2035), relative to base case (no intervention).
Results Of the policies evaluated, targeting PrEP preferentially to Black individuals would result in the largest reductions in incidence and disparities. This outcome was robust to different partnership preference assumptions, though the magnitude of impact differs.
Limitations We limit analysis to MSM, who bear the majority of HIV/AIDS burden in LAC. We do not consider transmission via injection drug use or mother-to-child transmission, nor do we capture individual network transmission effects. We assume no improvements in the prevention-diagnosis-treatment cascade besides increased PrEP use.
Conclusions We find there is little trade-off between effectiveness and equality of outcome when choosing groups to target for PrEP in LAC – by focusing on MSM with the highest HIV incidence (Black), we can reduce both overall infections and racial/ethnic disparities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the California HIV/AIDS Research Program (RP15-LA-007) and the UCLA Center for HIV Identification, Prevention and Treatment Services (P30 MH058107), CHIPTS, and the UCLA Center for AIDS Research (CFAR), UCLA AIDS Institute and USC Keck School of Medicine Seed Grant for Cross-Campus Collaboration. The funding sources had no role in the study design, data analysis and interpretation, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UCLA and LAC Institutional Review Boards have determined this study to be exempt (IRB#19-000110).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Support: This work was supported by the California HIV/AIDS Research Program (RP15-LA-007) and the UCLA Center for HIV Identification, Prevention and Treatment Services (P30 MH058107), CHIPTS, and the UCLA Center for AIDS Research (CFAR), UCLA AIDS Institute and USC Keck School of Medicine Seed Grant for Cross-Campus Collaboration. The funding sources had no role in the study design, data analysis and interpretation, decision to publish, or preparation of the manuscript.
Data Availability
Model parameters are provided in the attached appendix
